ILMN Stock Overview
Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for ILMN from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$155.15 |
| 52 Week High | US$156.66 |
| 52 Week Low | US$89.00 |
| Beta | 1.13 |
| 11 Month Change | 11.09% |
| 3 Month Change | 25.57% |
| 1 Year Change | 45.03% |
| 33 Year Change | -59.72% |
| 5 Year Change | -48.01% |
| Change since IPO | 692.15% |
Recent News & Updates
Illumina: Q3 Confirms Improving Fundamentals
Nov 05We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt
Oct 21
Recent updates
Illumina: Q3 Confirms Improving Fundamentals
Nov 05We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt
Oct 21Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
Aug 21Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation
Jul 23Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk
Jul 01Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out
Jun 28Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?
May 26Illumina: Expect A Slow Rebound
May 07Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)
Apr 26Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)
Mar 20Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition
Feb 23Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Jan 26Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024
Jan 19Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%
Dec 21Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?
Dec 03Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Oct 24Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?
Oct 03At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?
Aug 22The Big Trends: New Frontiers in Healthcare
Jul 13
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)
Jul 03Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt
Jun 13Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Apr 12Is Illumina (NASDAQ:ILMN) Using Too Much Debt?
Mar 14Shareholder Returns
| ILMN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 7.6% | 3.8% | 5.1% |
| 1Y | 45.0% | 21.2% | 37.7% |
Return vs Industry: ILMN exceeded the US Life Sciences industry which returned 21.2% over the past year.
Return vs Market: ILMN exceeded the US Market which returned 37.7% over the past year.
Price Volatility
| ILMN volatility | |
|---|---|
| ILMN Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ILMN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ILMN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,615 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Illumina, Inc. Fundamentals Summary
| ILMN fundamental statistics | |
|---|---|
| Market cap | US$24.08b |
| Earnings (TTM) | -US$1.58b |
| Revenue (TTM) | US$4.39b |
5.6x
P/S Ratio-15.5x
P/E RatioIs ILMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILMN income statement (TTM) | |
|---|---|
| Revenue | US$4.39b |
| Cost of Revenue | US$1.42b |
| Gross Profit | US$2.97b |
| Other Expenses | US$4.55b |
| Earnings | -US$1.58b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.99 |
| Gross Margin | 67.61% |
| Net Profit Margin | -36.10% |
| Debt/Equity Ratio | 93.6% |
How did ILMN perform over the long term?
See historical performance and comparison